Enzymatic analysis of biomarkers for the monitoring of Gaucher patients in Colombia

• A close relation between DBS and serum samples for chitotriosidase analysis allowed to validate DBS as a reliable sample.
• We could standardize two microtechniques for chitotriosidase and ACE analysis in serum samples.
• We found a significant correlation between the 2 biomarkers analyzed, making them reliable to monitor patients in Colombia.

IntroductionGaucher disease is caused by a deficiency of the enzyme acid beta-glucosidase. There is treatment available, but given the wide variability in phenotypes, it is difficult to establish the adequate administration and change of doses. Chitotriosidase and angiotensin converting enzyme (ACE) have been described as reliable biomarkers for the monitoring of patients. The enzymatic evaluation of these biomarkers has been traditionally made in serum or plasma samples, making difficult the monitoring of Colombian patients who live far away from big cities. Dried blood spot samples have been proposed as a solution. The aim of the present study was to validate the chitotriosidase quantification in DBS with respect to the serum determination, and to standardize a microtechnique for the quantification of serum ACE.ResultsUsing a fluorometric method for the chitotriosidase quantification and a colorimetric one for ACE determinations, we found significant differences between control subjects and Gaucher patients in both serum and DBS samples. A positive correlation was observed between both kinds of samples. A reference value for the ACE determination was established. A positive correlation between chitotriosidase and ACE was found.ConclusionWe could standardize two microtechniques for chitotriosidase and ACE analysis in serum samples. A close relation between DBS and serum samples for chitotriosidase analysis allowed us to validate DBS as a reliable sample that could facilitate the access of Colombian Gaucher patients to health services.